Autolus Therapeutics plc American Depositary Share (AUTL)
Stock · NASDAQ · Health Care
$1.59as of 10/16/2026
Price chart
Active signals
AUTL Signal Track Record
How signals performed across all stocks →What AUTL's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 39 | -1.9% | 44% | September 8, 2026 |
| Bollinger Band Breakout | 23 | -4.8% | 35% | August 3, 2026 |
| Bollinger Band BreakdownActive now | 20 | +4.8% | 60% | September 9, 2026 |
| 200-Day Moving Average TouchActive now | 8 | -1.2% | 50% | July 30, 2026 |
| Any 20-session window (baseline) | -2.1% | 45% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About AUTL
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 752
- Website
- www.autolus.com/
Fundamentals
- 1-day range
- $1.59$1.74
- Market cap
- $532.31M
- P/E (trailing)
- —
- P/E (forward)
- -2.51
- EPS (trailing)
- $-1.05
- Dividend yield
- —
- Beta
- 2.36
- Avg. volume
- 2.13M
How Autolus Therapeutics plc American Depositary Share Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 27, 2026 · via SEC EDGAR / Finnhub
Forecasts
8 analyst ratings
Autolus Therapeutics plc American Depositary Share Competitors
Chosen by industry and closest market cap.
- AUTLAutolus Therapeutics plc American Depositary Share$1.6▼ 6.98%Market cap $532.31MP/E —$1.18$2.58
- PRMEPrime Medicine Inc. Common Stock$3.47▼ 3.88%Market cap $532.82MP/E —$2.67$6.65
- DNAGinkgo Bioworks Holdings Inc. Class A Common Stock$10.27▼ 12.67%Market cap $528.15MP/E —$5.37$18.22
- ZURAZura Bio Limited Class A Ordinary Shares$3.88▼ 9.35%Market cap $542.44MP/E —$3.15$7.44
- FDMT4D Molecular Therapeutics Inc. Common Stock$12.14▼ 5.67%Market cap $551.51MP/E —$6.96$16.93
- EIKNEikon Therapeutics Inc. Common Stock$7.42▼ 1.59%Market cap $498.62MP/E —$6.45$17.4
- ARTVArtiva Biotherapeutics Inc. Common Stock$5.85▼ 3.47%Market cap $566.10MP/E —$2.75$14.53
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| AUTL Autolus Therapeutics plc American Depositary Share | $532.31M | — | $1.6 | ▼ 6.98% | $1.18$2.58 |
| PRME Prime Medicine Inc. Common Stock | $532.82M | — | $3.47 | ▼ 3.88% | $2.67$6.65 |
| DNA Ginkgo Bioworks Holdings Inc. Class A Common Stock | $528.15M | — | $10.27 | ▼ 12.67% | $5.37$18.22 |
| ZURA Zura Bio Limited Class A Ordinary Shares | $542.44M | — | $3.88 | ▼ 9.35% | $3.15$7.44 |
| FDMT 4D Molecular Therapeutics Inc. Common Stock | $551.51M | — | $12.14 | ▼ 5.67% | $6.96$16.93 |
| EIKN Eikon Therapeutics Inc. Common Stock | $498.62M | — | $7.42 | ▼ 1.59% | $6.45$17.4 |
| ARTV Artiva Biotherapeutics Inc. Common Stock | $566.10M | — | $5.85 | ▼ 3.47% | $2.75$14.53 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- All You Need to Know About Autolus Therapeutics (AUTL) Rating Upgrade to BuyYahoo · 10/5/2026
- Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026Yahoo · 10/5/2026
- Autolus Therapeutics Published Abstract Filed TO American College Of Rheumatology Convergence 2026Benzinga · 10/5/2026
- AUCATZYL Sales Are Exploding, But Autolus (AUTL) Still Isn’t In The BlackYahoo · 9/12/2026
Insider Activity
Insider Actions →- Piccina Cintia · September 2, 2026 · Sale6.7K @ $2.34
- Piccina Cintia · September 1, 2026 · Option Exercise20.0K @ $2.35
- Richardson Ryan · June 29, 2026 · Grant47.5K
- Richardson Ryan · June 29, 2026 · Grant31.7K
- Bain Linda · June 29, 2026 · Grant47.5K
- Rao Madduri Ravin · June 29, 2026 · Grant47.5K
- Rao Madduri Ravin · June 29, 2026 · Grant31.7K
- Leiderman Elisabeth · June 29, 2026 · Grant47.5K
- Leiderman Elisabeth · June 29, 2026 · Grant31.7K
- Robert Iannone · June 29, 2026 · Grant47.5K
- Robert Iannone · June 29, 2026 · Grant31.7K
- Robert Azelby · June 29, 2026 · Grant47.5K
- Robert Azelby · June 29, 2026 · Grant31.7K
- Bain Linda · June 29, 2026 · Grant31.7K
- Cynthia M. Butitta · June 29, 2026 · Grant47.5K
Institutional Ownership
March 31, 2026
- Total shares held
- 133.84M
- Total value held
- $183.50M
- Institutional holders
- 83
- Unknown33.62M
- Unknown20.49M
- Unknown16.64M
- Unknown15.80M
- Unknown9.50M
- Unknown9.49M
- Unknown4.45M
- Unknown3.36M
- Unknown3.32M
- Unknown2.30M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Autolus Therapeutics to Present Data at Rheumatology Conference
Autolus Therapeutics announced that an abstract has been filed for presentation at the American College of Rheumatology Convergence 2026. This event serves as a key venue for sharing clinical updates in the rheumatology field. The news provides a specific upcoming date for stakeholders to monitor potential data releases related to the company's pipeline.
Autolus Therapeutics to Present Data at Rheumatology Conference. Autolus Therapeutics announced that an abstract has been filed for presentation at the American College of Rheumatology Convergence 2026. This event serves as a key venue for sharing clinical updates in the rheumatology field. The news provides a specific upcoming date for stakeholders to monitor potential data releases related to the company's pipeline.